Last reviewed · How we verify
Morphine Retard
Morphine Retard is a sustained-release formulation of morphine that binds to opioid receptors in the central nervous system to provide prolonged pain relief.
Morphine Retard is a sustained-release formulation of morphine that binds to opioid receptors in the central nervous system to produce analgesia and reduce pain perception. Used for Chronic moderate to severe pain, Cancer pain.
At a glance
| Generic name | Morphine Retard |
|---|---|
| Also known as | Morphine |
| Sponsor | Huib A.M. Kerstjens |
| Drug class | Opioid analgesic |
| Target | Mu-opioid receptor (μ-opioid receptor) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Morphine is a mu-opioid receptor agonist that modulates pain perception and emotional response to pain by acting on opioid receptors throughout the brain and spinal cord. The retard (sustained-release) formulation extends the duration of action, allowing for less frequent dosing compared to immediate-release morphine while maintaining therapeutic opioid levels.
Approved indications
- Moderate to severe chronic pain
- Cancer pain
Common side effects
- Constipation
- Nausea
- Drowsiness
- Dizziness
- Vomiting
- Respiratory depression
Key clinical trials
- Morphine or Fentanyl for Refractory Dyspnea in COPD (PHASE4)
- Pharmacokinetics of Morphine and Oxycodone in Frail Elderly Undergoing Cardiac Surgery
- Pain Management After Elective Shoulder Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Morphine Retard CI brief — competitive landscape report
- Morphine Retard updates RSS · CI watch RSS
- Huib A.M. Kerstjens portfolio CI